NRX Pharmaceuticals Wins $11.2M Contract from Defense Advanced Research Projects Agency
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals, was awarded an $11.2 million prime contract from DARPA to conduct the SPARC-TMS clinical trial. The trial evaluates a single-day treatment protocol combining robotic neuro-navigated transcranial magnetic stimulation with the company's investigational drug, NRX-101, for treatment-resistant depression. The contract includes an initial obligation of $6.7 million with additional funding subject to appropriations and performance milestones.
- Value
- $11.2M
- Counterparty
- Defense Advanced Research Projects Agency (DARPA)
- Term
- 18 months